Cipla Limited Market Cap ($11.86 Billion)
Market Cap & Net Worth: Cipla Limited (CIPLA)
Cipla Limited market cap. Cipla Limited (NSE:CIPLA) has a market capitalization of $11.86 Billion (Rs1.10 Trillion) as of October 31, 2026. Listed on the NSE stock exchange, this India-based company holds position #1909 globally and #69 in its home market, demonstrating a 3.35% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cipla Limited's stock price Rs1358.00 by its total outstanding shares 807782631 (807.78 Million).
Cipla Limited Market Cap History (2015–2026)
Cipla Limited market cap history from 2015 to 2026. Data shows growth from $5.44 Billion to $11.86 Billion (6.83% CAGR). Check CIPLA stock price and chart for real-time trading data and today's change.
Index Memberships
Cipla Limited is a constituent of 9 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY PHARMA
CNXPHARMA
|
$101.93 Billion | 11.64% | #3 of 20 |
|
NIFTY GROWTH SECTORS 15
NI15
|
$239.73 Billion | 4.95% | #7 of 15 |
|
NIFTY 100
NIFTY100
|
$1.91 Trillion | 0.62% | #56 of 100 |
|
NIFTY100 EQUAL WEIGHT
NIFTY100EW
|
$1.66 Trillion | 0.72% | #44 of 99 |
|
NIFTY 200
NIFTY200
|
$2.40 Trillion | 0.49% | #62 of 200 |
|
NIFTY 500
NIFTY500
|
$2.95 Trillion | 0.40% | #64 of 500 |
|
NIFTY HEALTHCARE
NIFTYHEALTHCARE
|
$116.65 Billion | 10.17% | #5 of 20 |
|
Nifty Low Volatility 50
NIFTYLVI
|
$920.19 Billion | 1.29% | #22 of 48 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.04 Trillion | 0.39% | #64 of 750 |
Weight: Cipla Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cipla Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cipla Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Cipla Limited cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.05x
Cipla Limited's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.25x
Cipla Limited's market cap is 0.25 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.74 Billion | $135.48 Billion | $13.60 Billion | 0.03x | 0.35x |
| 2017 | $5.09 Billion | $143.34 Billion | $10.06 Billion | 0.04x | 0.51x |
| 2018 | $4.38 Billion | $151.05 Billion | $14.11 Billion | 0.03x | 0.31x |
| 2019 | $4.05 Billion | $163.23 Billion | $15.28 Billion | 0.02x | 0.27x |
| 2020 | $6.96 Billion | $170.81 Billion | $15.47 Billion | 0.04x | 0.45x |
| 2021 | $8.07 Billion | $191.21 Billion | $24.05 Billion | 0.04x | 0.34x |
| 2022 | $9.25 Billion | $217.08 Billion | $25.17 Billion | 0.04x | 0.37x |
| 2023 | $10.83 Billion | $225.59 Billion | $28.02 Billion | 0.05x | 0.39x |
| 2024 | $13.36 Billion | $255.37 Billion | $41.22 Billion | 0.05x | 0.32x |
| 2025 | $13.20 Billion | $272.67 Billion | $52.73 Billion | 0.05x | 0.25x |
Competitor Companies of CIPLA by Market Capitalization
Companies near Cipla Limited in the global market cap rankings as of October 31, 2026. See Cipla Limited balance sheet independence to understand what proportion of total assets are financed by equity.
Key companies related to Cipla Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #600 globally with a market cap of $45.38 Billion USD ( CN¥310.15 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #626 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.98 |
| #600 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.38 Billion | CN¥48.62 |
| #626 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €17.90 |
Market Capitalization of Cipla Limited (2015–2026)
Market capitalization of Cipla Limited from 2015 to today. Between 2015 and today, Cipla Limited's market cap moved from $5.44 Billion to $ 11.86 Billion, with a yearly change of 6.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs11.86 Billion | -10.14% |
| 2025 | Rs13.20 Billion | -1.16% |
| 2024 | Rs13.36 Billion | +23.36% |
| 2023 | Rs10.83 Billion | +17.02% |
| 2022 | Rs9.25 Billion | +14.64% |
| 2021 | Rs8.07 Billion | +15.92% |
| 2020 | Rs6.96 Billion | +71.79% |
| 2019 | Rs4.05 Billion | -7.38% |
| 2018 | Rs4.38 Billion | -14.08% |
| 2017 | Rs5.09 Billion | +7.43% |
| 2016 | Rs4.74 Billion | -12.83% |
| 2015 | Rs5.44 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Cipla Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.86 Billion USD |
| MoneyControl | $11.86 Billion USD |
| MarketWatch | $11.86 Billion USD |
| marketcap.company | $11.86 Billion USD |
| Reuters | $11.86 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cipla Limited
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, suc… Read more